Benzinga
11 Mar 2026, 18:11 UTC · 28w ago
Verdict
Headline takes no side. We score LGND +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Bank of America initiated coverage on Ligand Pharmaceuticals (LGND) with a Buy rating and a price target of $244.
More positive than 93% of claims this week
Ligand Pharmaceuticals beat Q4 consensus estimates with adjusted earnings of $2.02 per share and sales of $59.7 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
The company reaffirmed its fiscal 2026 adjusted earnings guidance of $8.00-$9.00 per share and sales guidance of $245 million to $285 million.
More positive than 63% of claims this week
Ligand possesses over $1 billion in deployable capital and a portfolio of over 100 programs for potential additional revenue.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Bank of America initiated coverage with a Buy rating, citing compelling upside and strong earnings beats.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
2h ago
+40.6%
Price agrees with the score
$298.41 vs $212.29 close before publication (Mar 10) · not market-adjusted
LGND chart →
